drug · antibody
faricimab
Marketedupdated 3mo agoby F. Hoffmann-La Roche Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 5 investigational indications.
indications
investigational
Diabetic Macular Edema
targets
Angiopoietin-2Vascular endothelial growth factor A, long form
all catalysts(5)
approval · 5
Jan 28, 2022
approval
VABYSMO (FARICIMAB-SVOA) — FDA approval
faricimab
→
Jan 27, 2023
approval
VABYSMO (FARICIMAB-SVOA) — FDA approval
faricimab
→
Oct 26, 2023
approval
VABYSMO (FARICIMAB-SVOA) — FDA approval
faricimab
→
Jul 3, 2024
approval
VABYSMO (FARICIMAB-SVOA) — FDA approval
faricimab
→
Apr 9, 2026
approval
VABYSMO (FARICIMAB-SVOA) — FDA approval
faricimab
→
Trials studying faricimab
- phase4A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
- phase3Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
- phase3Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
- phase3A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- —A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
- phase4A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
- phase1A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
- phase4Treat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
News(5)
- FDA scientists question Capricor data; Legend CEO steps downCapricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…biopharma_dive · 15d ago
- Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onRoche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker s…biospace · 19d ago
- Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapiesRoche may have scrapped work on a T-cell engager being evaluated for lupus, but the company’s head of pharma told Fierce that still has a strategy for developing cell therapies for autoimmune disea…fiercebiotech · 20d ago
- These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.biopharma_dive · 1mo ago
- Fierce Biotech Fundraising Tracker '26: Vaderis nets $152M series B; Epicrispr adds $90MThe Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs.fiercebiotech · 7mo ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that